Seemal Desai is a Dermatology physician affiliated with Plano Cancer Institute. OpenAlex indexes 154 publications with 3,702 citations (h-index 24).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
5655 W Spring Creek Pkwy Ste 105
Plano, TX 750244176
Telephone
214-919-3500Provider last certified this registry record 28 Jul 2025.
Industry payments
33 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Incyte CorporationProgram year202557 payments$61,903openpaymentsdata.cms.gov ↗
- PFIZER INC.Program year202525 payments$54,327openpaymentsdata.cms.gov ↗
- ABBVIE INC.Program year202529 payments$40,587openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
58.1%Azole Antifungal48%Ketoconazole100%Part D≥63 patientsTetracycline-class Drug10%Doxycycline Hyclate100%Part D≥20 patientsDermatology
18.6%Corticosteroid12.2%Triamcinolone Acetonide100%Part D≥32 patientsOther antifungals for topical use6.5%Ciclopirox100%Part D<11 patientsRespiratory
14%RNA Synthetase Inhibitor Antibacterial9%Mupirocin100%Part D≥23 patientsCorticosteroid5%Mometasone Furoate100%Part D≥13 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Delphi consensus on melasma management by international experts and pigmentary disorders society
Journal of the European Academy of Dermatology and Venereology
2025 - Global consensus on the management of melanin hyperpigmentation disorders
Journal of the European Academy of Dermatology and Venereology
2025 - Guidelines of care for the management of acne vulgaris
Journal of the American Academy of Dermatology
2024 - Integrating skin color assessments into clinical practice and research: A review of current approaches
Journal of the American Academy of Dermatology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Parita Bhuva, MD
Plano Cancer Institute
Crescens Pellecchia, DO
Plano Cancer Institute
Rosemarie Lajara, MD
Plano Cancer Institute
Ahmad Zankar, MD
Plano Cancer Institute
Robert Modlin, MD
University of California, Los Angeles
Heidi Kong, MD
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Jon Hanifin, MD
Oregon Health & Science University (OHSU)
Victoria Werth, MD
Perelman School of Medicine at the University of Pennsylvania
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”